Aadi Bioscience sells subsidiary for $100M, licenses ADC programs, raises $100M PIPE

Whitehawk Therapeutics, Inc.

Sells wholly owned subsidiary Private Aadi to Kaken Investments for $100M; stockholder approval required.
Licenses three pre-clinical ADC programs (MUC16, PTK7, SEZ6) from WuXi Biologics; upfront $44M total.
Raises $100M via PIPE: 21.6M shares at $2.40 and 20.1M pre-funded warrants at $2.3999.
Appoints Baiteng Zhao, Ph.D. (ex-ProfoundBio CEO) to Board; he committed $3M in PIPE.
Stockholder support agreements secured for ~36% of shares; termination fee $3.5M.

item 1.01 item 3.02 item 5.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.